SCHEMBL1966416

SCHEMBL1966416

CC(C)(C)OC(=O)N1CCN(/C(=N/O)c2cc(F)ccc2F)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.45
GPR119 Q8TDV5 1/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP3A4 P08684 1/20 0.42
CYP3A5 P20815 1/20 0.42
S1PR2 O95136 1/20 0.42
MAPT P10636 2/20 0.42
PLK1 P53350 1/20 0.41
POLB P06746 1/20 0.41
F13A1 P00488 1/20 0.41
TGM2 P21980 1/20 0.41
TGM1 P22735 1/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
STS P08842 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1966083 1.00 SMN1; SMN2 (0.45) SMN1; SMN2GPR119MEN1KMT2ACYP3A4
SCHEMBL1865525 0.86 SMN1; SMN2 (0.40) SMN1; SMN2GPR119MEN1KMT2ACYP3A4
SCHEMBL1865522 0.86 SMN1; SMN2 (0.40) SMN1; SMN2GPR119MEN1KMT2ACYP3A4
SCHEMBL12631925 0.86 POLB (0.47) GPR119MEN1KMT2AMAPTPOLB
SCHEMBL3089588 0.86 MEN1 (0.52) SMN1; SMN2GPR119MEN1KMT2AMAPT
SCHEMBL21383653 0.78 HDAC2 (0.44) SMN1; SMN2GPR119
SCHEMBL2846468 0.78 KDM4E (0.55) SMN1; SMN2MEN1KMT2AMAPTPOLB
SCHEMBL22532774 0.76 SMN1; SMN2 (0.56) SMN1; SMN2GPR119MEN1KMT2AMAPT
SCHEMBL111206 0.76 SMN1; SMN2 (0.56) SMN1; SMN2GPR119MEN1KMT2AMAPT
SCHEMBL224423 0.75 GPR119 (0.49) GPR119MEN1KMT2AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334657-B1 PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2013-03-06 EP disclosed
EP-2334657-A1 PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS F. Hoffmann-La Roche AG (CH) 2011-06-22 EP disclosed
US-7858630-B2 D3 and 5-HT2A receptor modulators HOFFMANN-LA ROCHE INC. (US) 2010-12-28 US disclosed
US-7858630-B2 D3 and 5-HT2A receptor modulators HOFFMANN-LA ROCHE INC. (US) 2010-12-28 US disclosed
US-7858630-B2 D3 and 5-HT2A receptor modulators HOFFMANN-LA ROCHE INC. (US) 2010-12-28 US disclosed
US-20100075983-A1 D3 AND 5-HT2A RECEPTOR MODULATORS HOFFMANN-LA ROCHE, INC. 2010-03-25 US disclosed
US-20100075983-A1 D3 AND 5-HT2A RECEPTOR MODULATORS HOFFMANN-LA ROCHE, INC. 2010-03-25 US disclosed
US-20100075983-A1 D3 AND 5-HT2A RECEPTOR MODULATORS HOFFMANN-LA ROCHE, INC. 2010-03-25 US disclosed
WO-2010031735-A1 PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075983-A1 D3 AND 5-HT2A RECEPTOR MODULATORS HTR2A, HTR3A, HTR1A SMN1; SMN2 3217/4885GPR119 159/4885MEN1 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.